1045 related articles for article (PubMed ID: 27127178)
1. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
4. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
5. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
6. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
10. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
11. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
14. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
15. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
16. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
17. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
19. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
20. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
